Women’s Attitudes Toward Invasive and Noninvasive Testing When Facing a High Risk of Fetal Down Syndrome by Seror, Valérie et al.
HAL Id: hal-02262523
https://hal-amu.archives-ouvertes.fr/hal-02262523
Submitted on 25 Jun 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
Women’s Attitudes Toward Invasive and Noninvasive
Testing When Facing a High Risk of Fetal Down
Syndrome
Valérie Seror, Olivier L’haridon, Laurence Bussières, Valérie Malan, Nicolas
Fries, Michel Vekemans, Laurent Salomon, Yves Ville
To cite this version:
Valérie Seror, Olivier L’haridon, Laurence Bussières, Valérie Malan, Nicolas Fries, et al.. Women’s At-
titudes Toward Invasive and Noninvasive Testing When Facing a High Risk of Fetal Down Syndrome.
JAMA Network Open, American Medical Association, 2019, 2 (3), pp.e191062. ￿10.1001/jamanet-
workopen.2019.1062￿. ￿hal-02262523￿
Original Investigation | Obstetrics andGynecology
Women’s Attitudes Toward Invasive and Noninvasive TestingWhen
Facing a High Risk of Fetal Down Syndrome
Valerie Seror, PhD; Olivier L’Haridon, PhD; Laurence Bussières, PhD; Valérie Malan, MD, PhD; Nicolas Fries, MD; Michel Vekemans, MD, PhD; Laurent J. Salomon, MD, PhD;
Yves Ville, MD; for the SAFE 21 Study Group
Abstract
IMPORTANCE Noninvasive prenatal testing (NIPT) using cell-free DNA inmaternal blood is
increasingly common compared with invasive testing (IT) in routine antenatal detection of Down
syndrome (DS).
OBJECTIVE To assess attitudes and decisionmaking in pregnant women facing a risk of fetal DS
greater than 1 in 250 as established by combined first trimester screening at 11 to 14 weeks of
gestation.
DESIGN, SETTING, AND PARTICIPANTS Survey study in which data were collected from pregnant
women at high risk of fetal DS participating in a randomized clinical trial. Data were collected from
April 8, 2014, to April 7, 2016, in 57 prenatal diagnosis centers in France. Data were analyzed in 2018.
INTERVENTIONS Data on attitudes were collected prior to offering randomization between NIPT
and IT, whereas data on decisionmaking and test results were collected as part of the clinical trial.
MAINOUTCOMEANDMEASURES The primary outcome related to attitudes. A hierarchical cluster
analysis was conducted to identify clusters with contrasting attitudes. Logistic regression analyses
were used to identify factors associated with attitudes.
RESULTS All 2436 consecutive women to whom the study was proposed (mean [SD] age, 36.3 [5.0]
years) answered the questionnaire: 515 (21.1%) expressed preference toward IT with complete
karyotyping, whereas 1843 (75.7%) favored NIPT with almost certain but limited information.
Hierarchical cluster analysis yielded 4 different clusters that mainly differed in attitudes toward risk
taking and extent of information seeking. Factors likely associated with attitudes driven by risk
aversion were mostly age and religious beliefs (adjusted odds ratio [aOR], 1.03; 95% CI, 1.00-1.05;
P = .03 and aOR, 1.62; 95%CI, 1.29-2.04; P < .001, respectively), whereas higher nuchal translucency
measurements by ultrasonography were associated with attitudes driven by ambiguity aversion
(aOR, 1.67; 95% CI, 1.27-2.20; P < .001). For attitudes involving both risk and ambiguity aversion at
different extents, lower education was associated with highly valuing all possibilities of getting
information on pregnancy, whereas higher education was associated with highly valuing information
on fetal DS as a primary concern (aOR, 0.54; 95% CI, 0.44-0.67; P < .001 and aOR, 1.44; 95% CI,
1.20-1.74; P < .001, respectively). In all, decisionmaking was in line with attitudes.
CONCLUSIONS ANDRELEVANCE Aversion to risk of fetal loss related to IT and aversion to
ambiguity generated by incomplete information fromNIPT played amajor role in shaping attitudes
and decisionmaking. Informed decisionmaking should require pregnant women at high risk of DS to
receive extensive information on targeted abnormalities by both tests.
JAMA Network Open. 2019;2(3):e191062. doi:10.1001/jamanetworkopen.2019.1062
Key Points
Question What are the attitudes and
decision making concerning invasive
and noninvasive prenatal testing in
women at high risk of fetal Down
syndrome?
Findings In a survey study of 2436
pregnant women in France participating
in a randomized clinical trial, 4 clusters
were identified with different attitudes
toward risk taking and extent of
information seeking. Decisionmaking
was in line with attitudes, and clinical
and socioeconomic factors were likely
associated with the attitudes identified.
Meaning Aversion to ambiguity
generated by incomplete information
from noninvasive testing as well as
aversion to risk of pregnancy loss due to
invasive testing played amajor role in
shaping attitudes and decisionmaking;
therefore, pregnant women should
receive extensive information on
targeted abnormalities by both tests to
aid informed decisionmaking.
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Introduction
Prenatal screening for Down syndrome (DS) is widely performed at 11 to 14 weeks of gestation by
using a combination ofmaternal age, measurements of fetal nuchal translucency by ultrasonography,
andmaternal serum concentrations of free human chorionic gonadotropin and plasma protein A.1
Various cutoffs of risk have been chosen to offer invasive testing (IT) as a second step, usually
between 1 in 100 and 1 in 300.1 More recently, noninvasive prenatal testing (NIPT) using cell-free
DNA circulating in maternal plasma has emerged as an intermediate step within a conditional
screening algorithm, as the positive predictive value of combined screening is around 1 in 16 for DS.2-7
In contrast with IT, which involves a risk of miscarriage but provides full information on all possible
chromosomal abnormalities, NIPT carries no risk of miscarriage but only provides information on the
targeted abnormalities and only in terms of very high likelihood of their presence or absence. Indeed,
the accuracy of cell-free-DNA to detect DS is around 99%with a 0.1% false-positive rate, and IT is
carried out to confirm a positive result.8 As a result, NIPT therefore involves both a risky, although
almost certain, component about targeted abnormalities together with an uncertain component
about nontargeted abnormalities. In addition to the well-known attractiveness of certainty in
decisionmaking (also known as the certainty effect9,10), presenting information involving both risky
and uncertain components is known to trigger ambiguity aversion11,12 as a result of a preference for
known risks (probabilities) over unknown risks.13 Decision making between IT and NIPT could
therefore be driven by aversion toward ambiguous information as much as by IT-related pregnancy
loss risk aversion.
The present study aimed to explore attitudes of pregnant womenwho are about to make their
decision following positive combined screening for DS. Considering the question addressed about
the possible role of ambiguity aversion in addition to risk aversion in shaping preferences and
decisionmaking, this study involved assessing attitudes, factors likely associated with attitudes, and
consistency between attitudes and actual decisionmaking in high-risk women invited to participate
in a multicenter randomized trial of IT vs NIPT.14
Methods
Data on pregnant women’s attitudes were collected within the framework of a randomized clinical
trial comparing risk and effectiveness of NIPT and IT at a national level, involving 57 prenatal
diagnosis centers (ClinicalTrials.gov identifier NCT02127515). Womenwith a fetal DS gestation-specific
risk of 1 in 250 or greater following combined screening were invited to enroll in the clinical trial. They
received one-on-one extensive information and counseling on the significance of this result as well
as on advantages and risks attached to both IT and NIPT options.14 More specifically, the information
provided to all participants as to the risks and benefits of each group of the study included issues relating
to culture failure andmosaicismwith IT as well as the chance of false-negative results with NIPT. The
extent of counselling was intended tominimize the role of the heterogeneity of women’s access to
relevant information prior to prenatal screening. Pregnant womenwere then asked to fill out a self-
administered electronic questionnaire on site (eAppendix in the Supplement) exploring their attitude
toward IT and NIPT in this high-risk situation. They were then asked to participate in the randomized
clinical trial comparing NIPT and IT. Participants provided written informed consent and the study
received ethics committee approval as part of themulticenter randomized trial. This study followed
the American Association for Public Opinion Research (AAPOR) reporting guideline.
Exclusion criteria were multiple pregnancies and nuchal translucencymeasurements over 3
mm, as this could be amarker of other submicroscopic chromosomal disorders that would not be
detectable by NIPT and only by IT. Another exclusion criterion was the absence of medical coverage
by the French national health insurance system. Women who declined to participate in the trial,
whether they refused prior to randomization between IT vs NIPT or their randomized assignment to
NIPT, still had the possibility of undergoing ITwithout extra charges because thesewomen remained
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eligible for full coverage by the French national health insurance system. On the contrary, women
who refused their randomized assignment to IT and then decided to undergo NIPT had to pay for it.
As a result, opting for IT after negative NIPT led to pregnancy risk taking without financial cost,
whereas declining IT to opt for NIPT did not involve pregnancy risk taking but was financially costly.
Questionnaire
In addition to sociodemographic characteristics, the questionnaire included 23 questions on decision
making about DS screening, understanding of combined screening test results, and attitudes toward
IT-related fetal loss as compared with the birth of a child with DS. Specifically, the questionnaire
addressed attitudes about the trade-off between risk taking and extent of information seeking,
preferences between carrying out IT and NIPT, preference-basedmeasurements using visual analog
scales (VAS; from 0-10 with higher or lower scores indicating stronger preference for IT or NIPT,
respectively), and decisional attitudes. Risk of fetal loss related to IT was rated to be around 1% as it
is mentioned on French informed consent forms. Lastly, clinical data were available from the trial,
including nuchal translucency measurements, calculated risk of DS from combined screening,
gravidity, parity, smoking status, and IT uptake and diagnosis of chromosomal abnormalities in
previous pregnancies. Miscarriages in previous pregnancies were also identified.
Statistical Analysis
Women’s attitudes were assessed using a hierarchical cluster analysis15 aiming to allocate individuals
to groups as suggested by the recorded data; these groupswere therefore not defined a priori. Using
the Euclideanmetric to compute distances between individuals and to cluster them,16 the
agglomerative hierarchical procedure first involved each observation to be a cluster by itself. Then,
the 2 closest clusters were merged to form a new one, and this procedure was repeated until only 1
cluster was left.17 The optimum number of clusters was determined using a 2-fold criterion:
minimization of the interindividual distances within a cluster (within-group homogeneity) and
maximization of the distances between the centers of gravity of clusters (between-cluster
heterogeneity). Individuals in a given cluster tended to be similar for the variables selected for
analysis, while individuals with contrasting characteristics were allocated to different clusters. Typical
patterns of attitudes were thus identified as a result of the hierarchical cluster analysis. Each cluster
was characterized by the variables that contributed significantly to its formation, using P values
calculated bymultiscale bootstrap resampling methods. Because of collinearity issues between the
variables relating to women’s preferences and associated VAS scores, VAS scores were used as an
illustrative variable that was not involved in the calculations but was used to illustrate statistical
results. The hierarchical cluster analysis was carried out using the SPAD software package (Coheris).
Statistical analysis also involved logistic regressions to assess the relative effects of various
factors on women’s attitudes. All variables associated with a P value less than .10 in the univariate
analyses were taken to be eligible for themultivariable analysis. Using a backward selection
procedure, only variables remaining independently and significantly associated with the outcome
with a 2-tailed P value less than .05 were kept in the final model.
Results
The present study was proposed to 2592 consecutive pregnant women at high risk for fetal DS from
April 8, 2014, to April 7, 2016. Among thesewomen, 33 declined to participate in the trial and refused
to fill out the questionnaire, whereas 123 participated in the trial but did not fill out the questionnaire.
As a result, 2436 questionnaires of consecutive pregnant women at high risk for DS were studied
(Figure).
Clinical and sociodemographic characteristics of the women together with their understanding
of their own risk of fetal DS are presented in Table 1. Overall, mean (SD)maternal agewas 36.3 (5.0)
years, 12.6% had IT in a previous pregnancy, and 4.2% experienced fetal chromosomal abnormalities
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in a previous pregnancy. Fetal risk of DS ranged from0.004 to 0.20 (mean, 0.01). In addition,
two-thirds of the women reached at least upper secondary educational level, and about a third
reported religion to be very or fairly important to them. Self-assessment of their level of risk for DS
was consistent with the calculated risk from combined screening (P < .001): a 0.0203 average
calculated risk was observed in the pregnant womenwho considered their risk as very high, whereas
a 0.0101 and 0.0075 average calculated risk was associated to perceived risk as high or rather low,
respectively. However, women with an educational level below secondary school graduation were
more likely than others to consider their risk to be rather low (36.1% vs 21.2%; P < .001). In addition,
women unable to appraise their level of risk weremore likely to be at lower risk (mean risk at 0.0088
vs 0.0110; P = .02).
Attitudes TowardNIPT and IT
Using data relating to pregnant women’s attitudes (Table 1), the hierarchical cluster analysis yielded
4 different clusters. The variables characterizing each one of these clusters are presented in Table 2.
The first cluster (10.3% [250 of 2436 respondents]) consisted of womenwho highly valued the
possibility of getting all possible information on chromosomal abnormalities without any delay. These
women reportedmore frequently than the others that they had anticipated the possibility of having
to decide about IT in case of a high risk of DS (36.8% vs 28.8%; difference, 8.0%; 95% CI,
17.4%-14.6%; P = .006). Most of them considered the risk of IT-related fetal loss to be acceptable
while providing access to all possible information on fetal chromosomal abnormalities (85.6% vs
34.9%; difference, 50.7%; 95% CI, 45.2%-55.2%; P < .001) and preventing further anxiety (52.0%
vs 33.9%; difference, 18.1%; 95% CI, 11.4%-24.7%; P < .001). Women in this cluster expressed a
clear-cut preference for IT (79.6% vs 14.5%; difference, 65.1%; 95% CI, 59.3%-70.1%; P < .001) and
considered declining NIPT if offered (87.3% vs 0%; difference, 87.3%; 95% CI,
82.3%-91.0%; P < .001).
The second cluster (19.91% [485 respondents]) included womenwho valued all possibilities of
getting information on their pregnancy. They frequently stated, as in the previous cluster, that the
birth of a baby with DS was a worse pregnancy outcome than IT-related fetal loss (63.9% vs 54.4%;
difference, 9.5%; 95% CI, 4.5%-14.3%; P < .001) and that getting all possible information on
chromosomal abnormalities was worth the risk of fetal loss (50.1% vs 37.6%; difference, 12.5%; 95%
CI, 7.5%-17.6%; P < .001). While women in this cluster also deemed that having undergone DS
screening should prompt women to carry out IT if offered (58.4% vs 29.1%; difference, 29.3%; 95%
CI, 24.2%-34.1%; P < .001), they did not express clear-cut preference between IT and NIPT (18.8% vs
21.7%; difference, 2.9%; 95% CI, −1.3% to 6.8%; P = .08) and they accordingly viewed carrying out
Figure. Participant Flowchart
1729 Included in the SAFE 21 trial
2436 High-risk pregnant women asked to participate in the
SAFE 21 trial
1991 Accepted randomization between IT and NIPT
750 Randomized to IT
group
979 Randomized to NIPT
group
78 Received IT
4 Carried out IT despite
negative NIPT
1 Declined IT
7 Randomized to NIPT
group
255 Randomized to
IT group
53 Carried out NIPT
445 Declined participation in the SAFE 21 trial
262 Refused further participation following randomization
IT indicates invasive testing; NIPT, noninvasive
prenatal testing.
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Table 1. Clinical and Sociodemographic Characteristics, Understanding of the Results of DS Combined
Screening Test, and Attitudes Toward IT and NIPT of 2436 PregnantWomen at High Risk for Fetal DS
Characteristic No (%)
Age, mean (SD), y 36.3 (5.0)
Nuchal translucency measurement, mean (SD), multiple of the median 0.6901 (0.5034)
DS risk: combined test results, mean (SD), multiple of the median 0.0108 (0.0124)
No prior pregnancy 604 (24.4)
Nulliparous 799 (32.8)
Invasive testing in previous pregnancies 306 (12.6)
Diagnosis of fetal chromosomal abnormalities in previous pregnancies 103 (4.2)
Current smoker 441 (18.1)
Time of inclusion with respect to first inclusion, mean (SD), d 382.11 (182.433)
Educational level
No education or primary education 146 (6.0)
Lower secondary education 449 (18.4)
Secondary education 359 (14.7)
Upper secondary education 435 (17.9)
Postsecondary and tertiary education 1003 (41.2)
Missing 44 (1.8)
Religion
Very important 289 (11.9)
Fairly important 426 (17.5)
Not very important 615 (25.2)
Not important at all 1039 (42.6)
Missing 67 (2.7)
Women’s understanding of combined test
Rather low risk 611 (25.1)
High risk 1256 (51.6)
Very high risk 347 (14.2)
Other: comments on screening and DS risk 181 (7.4)
Missing 41 (1.7)
Decision-making about biochemical screening
Decided to carry it out before the option was proposed 1030 (42.3)
Did not think about it before the option was proposed 1000 (41.0)
Did not know about it before the option was proposed 392 (16.1)
No opinion 14 (0.6)
While awaiting the combined test results, anticipated decision about invasive testing?
Yes 726 (29.8)
No 1680 (69.0)
No opinion 30 (1.2)
Worst pregnancy outcome, in the women’s opinion
Birth of a child with DS 1371 (56.3)
Miscarriage due to invasive testing 933 (38.3)
No opinion 132 (5.4)
What is best?
To take the risk of procedure-related fetal loss (occurring in approximately 1 woman
in 100) and obtain certain information on all possible chromosomal abnormalities
976 (40.1)
Not to take the risk of procedure-related fetal loss and get almost certain information
(99% reliability) on DS only
1388 (57.0)
No opinion 72 (3.0)
Women’s preferences between IT and NIPT
Neither IT nor NIPT 29 (1.2)
NIPT 1843 (75.7)
IT 515 (21.1)
No opinion 49 (2.7)
(continued)
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both NIPT and then IT as their preferred option (95.1% vs 66.5%; difference, 28.6%; 95% CI, 25.4%-
31.3%; P < .001).
The third cluster (54.4% [1324 respondents]) included womenwho primarily valued getting
information on fetal DS. Women in this cluster had decidedmore frequently than the others to
undergo biochemical screening before it was even proposed (45.6% vs 38.3%; difference, 7.3%; 95%
CI, 3.3%-11.3%; P < .001). Like in previous clusters, most women considered that the birth of a baby
with DS was a worse pregnancy outcome than IT-related fetal loss (58.8% vs 53.2%; difference,
5.6%; 95% CI, 1.6%-9.6%; P = .003). However, all of them deemed that IT should not be undergone
without considering the decisional implications (100% vs 45.4%; difference, 54.6%; 95% CI,
51.6%-57.5%; P < .001) and they also frequently stated that getting complete information on all
possible chromosomal abnormalities was not worth the risk for the pregnancy (64.1% vs 54.9%;
difference, 9.2%; 95% CI, 5.2%-13.1%; P < .001). While they expressed preference toward NIPT
(84.6% vs 72.0%; difference, 12.6%; 95% CI, 9.2%-15.9%; P < .001), they did not reject the IT option
at the time when they were offered to participate in the trial because nearly all considered carrying
out IT following a negative NIPT (98.0% vs 41.5%; difference, 56.5%; 95% CI,
53.4%-59.5%; P < .001).
Table 1. Clinical and Sociodemographic Characteristics, Understanding of the Results of DS Combined
Screening Test, and Attitudes Toward IT and NIPT of 2436 PregnantWomen at High Risk for Fetal DS
(continued)
Characteristic No (%)
Visual analog scale score, mean (SD)a 3.09 (3.25)
Decisional preferences after having been informed about the trial
To decline both IT and NIPT 25 (1.0)
To carry out NIPT if offered and to decline IT otherwise 357 (14.7)
To carry out NIPT provided also carrying out IT 1758 (72.2)
To carry out IT and to decline NIPT 218 (8.9)
No opinion 78 (3.2)
It is best to take the risk of procedure-related fetal loss rather than to be worried until
the end of the pregnancy
Strongly agree 872 (35.8)
Rather agree 1019 (41.8)
Rather disagree 346 (14.2)
Strongly disagree 182 (7.5)
No opinion 17 (0.7)
Having carried out biochemical screening should lead women to undergo invasive
testing if it is advised by their health care professional
Strongly agree 851 (34.9)
Rather agree 986 (40.5)
Rather disagree 372 (15.3)
Strongly disagree 204 (8.4)
No opinion 23 (0.9)
Invasive testing should be declined when termination of pregnancy is not an option in
the case of DS
Strongly agree 713 (29.3)
Rather agree 681 (28.0)
Rather disagree 552 (22.7)
Strongly disagree 466 (19.1)
No opinion 24 (1.0)
Invasive testing should be carried out without considering the decisions that might be
required following its results: everything in its own time
Strongly agree 607 (24.9)
Rather agree 778 (31.9)
Rather disagree 641 (26.3)
Strongly disagree 389 (16.0)
No opinion 21 (0.9)
Abbreviations: DS, Down syndrome; IT, invasive
testing; NIPT, noninvasive prenatal testing.
a Visual analog scale from 0 to 10, with lower values
indicating stronger preference for NIPT.
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The fourth cluster (15.5% [377 respondents]) consisted of womenwhose attitudes appeared to
be driven by aversion to the risk of IT-related fetal loss (72.1% vs 38.5%; difference, 33.6%; 95% CI,
28.3%-38.5%; P < .001). Accordingly, most of them would choose not to take any risk with the
pregnancy and get information on DS only (88.3% vs 54.7%; difference, 33.6%; 95% CI,
28.3%-38.5%; P < .001). Women in this cluster expressed a clear-cut preference for NIPT (94.4% vs
76.0%; difference, 18.4%; 95% CI, 15.0%-21.2%; P < .001) and approximately one-third of them
deemed that IT should be declined when termination of the pregnancy is not an option (35.3% vs
28.2%; difference, 7.1%; 95% CI, 1.9%-12.6%; P = .004).
Perceived values attached to IT and NIPT as rated with a VAS showed the highest scores for IT
were found in cluster 1 (89.2% of VAS scores greater than 5 vs 27.1% in the other clusters; difference,
62.1%; 95% CI, 57.0%-66.0%; P < .001) while the lowest scores were found in cluster 4 (9.3% vs
37.9%; difference, 28.6%; 95%CI, 13.0%-19.5%; P < .001). Otherwise, women in cluster 2 had higher
VAS scores than women in cluster 3, which was also consistent with more frequent ratings greater
than 5 in cluster 2 (37.9% vs 28.2%; difference, 9.7%; 95% CI, 4.7%-14.8%; P = .02).
Factors AssociatedWith Attitudes
The factors associated with women’s attitudes toward NIPT and IT are presented in Table 3. Women
with higher nuchal translucencymeasurements by ultrasonographyweremore likely to be included
in cluster 1 (adjusted odds ratio [aOR], 1.67; 95% CI, 1.27-2.20; P < .001), whereas cluster 2 was more
likely to include women with lower educational levels (aOR, 0.54; 95% CI, 0.44-0.67; P < .001).
Women in cluster 3 were characterized by higher educational levels (aOR, 1.44; 95% CI, 1.20-1.74;
P < .001) and lower importance given to religion (aOR, 0.68; 95% CI, 0.57-0.82; P < .001). Lastly,
older women (aOR, 1.03; 95% CI, 1.00-1.05; P = .03), those who described their own risk of DS as
rather low (aOR, 1.34; 95% CI, 1.05-1.71; P = .02), and those with very or fairly strong religious beliefs
(aOR, 1.62; 95% CI, 1.29-2.04; P < .001) were more likely to be included in cluster 4. Allocations to
cluster 1 decreased slightly over time throughout the trial (aOR, 0.99; 95% CI, 0.99-0.99; P < .001),
whereas allocations increased slightly over time in cluster 3 (aOR, 1.01; 95% CI, 1.00-1.01; P = .009).
WasDecisionMaking in LineWith Attitudes?
Overall, pregnant women’s decisions were consistent with their attitudes (Table 4). Womenwho
refused participation in the trial prior to randomization were primarily found to be included in cluster
1 (78.8% vs 11.3% distributed among the other clusters; P < .001). These womenweremainly
characterized with higher nuchal translucencymeasurements by ultrasonography (median at 0.80
vs 0.67; P = .003) and fewer experiences of fetal loss (13.2% of women in cluster 1 reporting 0 or 1
previous experience of fetal loss vs 9.9% in the other women; P = .001). As for refusal of randomized
assignment to IT, the lowest rate was in cluster 1 (1.2%), while the highest was in cluster 4 (44.3%).
In all, 43.2% of women in cluster 4, representing 6.7% of the surveyed women, declined to
participate in the trial either before or after randomization. In addition, most women opting for NIPT
after having declined IT were included in clusters 3 and 4 (60.4% and 22.6%, respectively, vs 17.0%
for the other clusters; P < .001).
Discussion
The present study confirmed pregnant women’s preference toward NIPT18-27 and showed highly
contrasted attitudes toward IT andNIPT in pregnant women at high risk of fetal DS by combined first-
trimester screening. A clear-cut preference for IT (cluster 1) was associated with risk aversion to
IT-related fetal loss being outweighed by aversion to ambiguous information on fetal chromosomal
abnormalities other than DS, leading to lower VAS scores for NIPT. In contrast, clear-cut preference
for NIPT (cluster 4) was expressed by women with strong aversion to IT-related risk of fetal loss,
confirming previous findings18,19,24,25 and being consistent with highest VAS scores attached to NIPT.
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In between, attitudes in clusters 2 and 3 involved both risk aversion and ambiguity aversion to
different extents.
In addition, pregnant women’s trade-offs between pregnancy risk taking and extent of
information seeking were found to differ depending on DS risk levels. Womenwho considered their
own risk of fetal DS following combined test results as being rather low were more likely to report
strong aversion to IT-related risk (cluster 4). In contrast, those with higher nuchal translucency
measurements were more likely to report strong aversion to ambiguity conveyed by NIPT results
(cluster 1). While DS risk assessment is combiningmultiple parameters (age, nuchal translucency, and
biochemical markers), a common behavioral bias, the base rate fallacy bias,28 could explain attitudes
in cluster 1. Base rate fallacy bias occurs when focusing on specific information, ie, the
ultrasonography component of DS risk, rather than on overall information on DS risk andmaking
inferences about the outcome. As a result, ultrasonographic screening could shape high-risk
women’s attitudes, just as age has been shown to shape attitudes toward IT among low-risk pregnant
women.29 Otherwise, the present studymainly confirmed the role played by education and religious
beliefs on attitudes.25,30
Relevance of risk aversion and ambiguity aversion in explaining attitudes was highlighted by
high consistency of attitudes with decision-making. Womenwith clear-cut preference for IT (cluster
1) were also more likely to decline to participate in the clinical study, suggesting that these women
acknowledged the uncertain component of the information provided by NIPT and expressed strong
aversion to ambiguity generated by incomplete information fromNIPT. Anothermain finding related
to the fact that few women underwent IT despite negative NIPT results, although approximately
70% of women considered undergoing IT in addition to NIPT as their preferred option. While
undergoing IT in addition to NIPT did not involve anymonetary constraints, the possibility of base
rate fallacy bias cannot be ruled out. Indeed, negative NIPT results could lead pregnant women to
implicitly extrapolate on the other chromosomal abnormalities not targeted by NIPT. In view of the
false reassurance possibly induced by negative NIPT results, further investigations should be
conducted on the extent to which base rate fallacy bias truly affects pregnant women’s decisions.
Otherwise, this study shows that the availability of NIPTmay reduce the refusal rates for further
testing,31 far from the commonly observed 20% rate of high-risk pregnant women’s refusal of IT
when NIPTwas not available.32-34 Lastly, this study also shows that approximately a third of pregnant
women anticipated their decision in the case of high risk of DS21 and that older pregnant women
attached higher value to NIPT than their younger counterparts.23
Table 4. Actual Decision-Making and Visual Analog Scale Values Attached to IT Depending on Clusters for 2436 PregnantWomen at High Risk
for Fetal Down Syndromea
Decision Total, No. (%)
Cluster 1 (n = 250) Cluster 2 (n = 485) Cluster 3 (n = 1324) Cluster 4 (n = 377)
No. (%) P Value No. (%) P Value No. (%) P Value No. (%) P Value
Refused participation prior to
randomization between IT and NIPT
445 (18.3) 197 (78.8) <.001 52 (10.7) <.001 146 (11.0) <.001 50 (13.3) .006
Refused their randomized
assignment to IT
255 (10.5) 3 (1.2) <.001 34 (7.0) .005 105 (7.9) <.001 113 (30.0) <.001
Accepted their randomized
assignment to:
IT 750 (30.8) 26 (10.4) <.001 176
(36.3)
.003 491 (37.1) <.001 57 (15.1) <.001
NIPT 979 (40.2) 22 (8.8) <.001 223
(46.0)
.004 579 (43.7) <.001 155 (41.1) .69
Opted for NIPT after having
declined ITb
506 (20.8) 5 (1.9) .59 73 (15.1) .67 799 (60.4) <.001 85 (22.6) <.001
Abbreviations: IT, invasive testing; NIPT, noninvasive prenatal testing.
a Cluster 1 was characterized by participants whowanted all possible information as soon
as possible (250 women [10.3%]); cluster 2, participants who wanted all possibilities
of getting information (485women [19.9%]); cluster 3, participants whowere primarily
concerned with information on DS (1324 women [54.3%]); and cluster 4, participants
characterized by aversion to risk of fetal loss (377 women [15.5%]).
b Calculations based on the 255 pregnant womenwho refused their randomized
assignment to IT.
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Limitations
Attitudes and behaviors were studied within the framework of a clinical trial, in which counseling is
likely to have been homogeneous and consistent in informing pregnant women about their
options.35 Informed decisions were therefore likely to have been facilitated, possibly beyond what
would be seen in routine antenatal practice. Another limitation was that DS was the only
chromosomal abnormality targeted by NIPT, although trade-offs between pregnancy risk taking and
extent of information seeking are likely to stand unless NIPT targets all chromosomal abnormalities
detectable using IT. Another limitation relates to the rapidly evolving field of molecular cytogenetics
that has recently identified comparative genomic hybridizationmicroarray to provide additional
information to the standard karyotype following IT. Although complete information should include
genomic hybridizationmicroarray on trophoblast or amniotic fluid, this option was not considered in
our study. A final limitation concerned the risk ofmiscarriage of 0.5% to 1.0% associatedwith IT that
was included in the information provided. There is now strong evidence that this risk is likely to be
overstated.14,36,37
Conclusions
The present study highlights themajor role played by risk aversion and ambiguity aversion in shaping
attitudes and decisionmaking. Availability of NIPT imposes complex decisions and informed decision
making that would require receiving extensive information on abnormalities targeted by both NIPT
and IT. Genetic counseling goes beyond the trade-off between first-line combined screening and
invasive procedure-related risk. While pregnant women have been shown to greatly differ in terms
of extent of information seeking, tolerance for uncertainty, and pregnancy risk taking, counseling
should involve listening to women’s preferences as to what they want to get out of prenatal testing.
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